ASCO 2024 – J&J flies towards a more convenient Rybrevant
Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.
ASCO 2024 preview – toxicity looms large for J&J
Four deaths cast doubt on J&J’s multi-pronged KLK2 push.
A new menin challenger
Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.
A Calquence win seven years in the making
AstraZeneca celebrates success in the Echo trial in mantle cell lymphoma, but watch out for BeiGene.
ASCO 2024 preview – Astra’s plenary double
Abstract titles reveal some of ASCO’s key datasets.
FibroGen throws down the prostate cancer gauntlet
Amid doubts about early data with FG-3246, the group is scathing about its rivals.
